ArrayExpress Uploader03287BT474lapatinib-sensitiveDMSOBT474lapatinib-sensitiveDMSOBT474lapatinib-sensitiveDMSOBT474lapatinib-sensitivelapatinibBT474lapatinib-sensitivelapatinibBT474lapatinib-sensitivelapatinibBT474-J4acquired lapatinib-resistantDMSOBT474-J4acquired lapatinib-resistantDMSOBT474-J4acquired lapatinib-resistantDMSOBT474-J4acquired lapatinib-resistantforetinibBT474-J4acquired lapatinib-resistantforetinibBT474-J4acquired lapatinib-resistantforetinibBT474-J4acquired lapatinib-resistantlapatinibBT474-J4acquired lapatinib-resistantlapatinibBT474-J4acquired lapatinib-resistantlapatinibBT474-J4acquired lapatinib-resistantlapatinib and foretinibBT474-J4acquired lapatinib-resistantlapatinib and foretinibBT474-J4acquired lapatinib-resistantlapatinib and foretinibarrayexpress_sid4These data provide scientific information to understand the mechanism of action of lapatinib resistance in HER2-positive patients and to...19671800E-GEOD-16179/profile/8773/arrayexpressuploader318celllineDec.12, 2014Falsebt474-and-bt474-j4-microarray-dataE-GEOD-16179_A-AFFY-44BT474 and BT474-J4 microarray dataSep.12, 2014These data provide scientific information to understand the mechanism of action of lapatinib resistance in HER2-positive patients and to test the combination of HER2-targeted agents and GSK1363089 (foretinib) in the clinic by using an acquired lapatinib-resistant cell line. Cell lines (BT474, an HER2-positive and lapatinib-sensitive cell line; BT474-J4, an acquired lapatinib-resistant cell line) were treated with lapatinib alone (1uM), foretinib (GSK1363089) alone (0.1 uM), a combination of lapatinib (1 uM) and foretinib (0.1 uM), or DMSO control for 24 hours. Triplicates were performed.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-16179humanhttp://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-16179/samples/